TY - JOUR
T1 - Low complement levels are related to poor obstetric outcomes in women with obstetric antiphospholipid syndrome. The EUROAPS Registry Study Group
AU - Esteve-Valverde, Enrique
AU - Alijotas-Reig, Jaume
AU - Belizna, Cristina
AU - Marques-Soares, Joana
AU - Anunciacion-Llunell, Ariadna
AU - Feijóo-Massó, Carlos
AU - Sáez-Comet, Luis
AU - Mekinian, Arsene
AU - Ferrer-Oliveras, Raquel
AU - Lefkou, Elmina
AU - Morales-Pérez, Stephanie
AU - Hoxha, Ariel
AU - Tincani, Angela
AU - Nalli, Cecilia
AU - Pardos-Gea, Josep
AU - Marozio, Luca
AU - Maina, Aldo
AU - Espinosa, Gerard
AU - Cervera, Ricard
AU - De Carolis, Sara
AU - Latino, Omar
AU - Udry, Sebastian
AU - Llurba, Elisa
AU - Garrido-Gimenez, Carmen
AU - Trespidi, Laura
AU - Gerosa, Maria
AU - Chighizola, Cecilia B.
AU - Rovere-Querini, Patrizia
AU - Canti, Valentina
AU - Mayer-Pickel, Karoline
AU - Tabacco, Sara
AU - Arnau, Anna
AU - Miró-Mur, Francesc
N1 - Publisher Copyright:
© 2023 Elsevier Ltd
PY - 2023/5
Y1 - 2023/5
N2 - Introduction: Obstetric antiphospholipid syndrome (OAPS) is an autoimmune disease related to antiphospholipid antibodies (aPL) with primaryinflammatory injury followed by clot cascade activation and thrombus formation. Complement system activation and their participation in aPL-related thrombosis is unclosed. Methods: We haveanalysed adverse pregnancy outcomes (APO) related to low complement (LC) levels in a cohort of 1048 women fulfilling classification criteria for OAPS. Results: Overall, 223 (21.3%) women presented LC values, during pregnancy. The length of pregnancy was shorter in OAPS women with LC compared to those with normal complement (NC) (median: 33 weeks, interquartile range: [24–38] vs. 35 weeks [27–38]; p = 0.022). Life new-born incidence was higher in patients with NC levels than in those with LC levels (74.4% vs. 67.7%; p = 0.045). Foetal losses were more related to women with triple or double aPL positivity carrying LC than NC values (16.3% vs. 8.0% NC; p = 0.027). Finally, some placental vasculopathies were affected in OAPS patients with LC as late Foetal Growth Restriction (FGR >34 weeks) rise to 7.2% in women with LC vs. 3.2% with NC (p = 0.007). Discussion: Data from our registry indicate that incidence of APO was higher in OAPS women with LC levels and some could be reverted by the correct treatment.
AB - Introduction: Obstetric antiphospholipid syndrome (OAPS) is an autoimmune disease related to antiphospholipid antibodies (aPL) with primaryinflammatory injury followed by clot cascade activation and thrombus formation. Complement system activation and their participation in aPL-related thrombosis is unclosed. Methods: We haveanalysed adverse pregnancy outcomes (APO) related to low complement (LC) levels in a cohort of 1048 women fulfilling classification criteria for OAPS. Results: Overall, 223 (21.3%) women presented LC values, during pregnancy. The length of pregnancy was shorter in OAPS women with LC compared to those with normal complement (NC) (median: 33 weeks, interquartile range: [24–38] vs. 35 weeks [27–38]; p = 0.022). Life new-born incidence was higher in patients with NC levels than in those with LC levels (74.4% vs. 67.7%; p = 0.045). Foetal losses were more related to women with triple or double aPL positivity carrying LC than NC values (16.3% vs. 8.0% NC; p = 0.027). Finally, some placental vasculopathies were affected in OAPS patients with LC as late Foetal Growth Restriction (FGR >34 weeks) rise to 7.2% in women with LC vs. 3.2% with NC (p = 0.007). Discussion: Data from our registry indicate that incidence of APO was higher in OAPS women with LC levels and some could be reverted by the correct treatment.
KW - Antibodies, Antiphospholipid
KW - Antiphospholipid Syndrome/complications
KW - Female
KW - Humans
KW - Male
KW - Placenta
KW - Pregnancy
KW - Pregnancy Complications
KW - Registries
UR - http://www.scopus.com/inward/record.url?scp=85151851249&partnerID=8YFLogxK
U2 - 10.1016/j.placenta.2023.04.001
DO - 10.1016/j.placenta.2023.04.001
M3 - Article
C2 - 37028222
AN - SCOPUS:85151851249
SN - 0143-4004
VL - 136
SP - 29
EP - 34
JO - Placenta
JF - Placenta
ER -